Current Trials

Clinical trials currently open for recruitment of participants is listed by cancer type. If you are interested in taking part in a clinical trial, please discuss with your doctor.

Please refer to the FAQs section of this website for answers to some commonly asked questions regarding clinical trials.

GO TO >> Leukaemia Trials | Lymphoma Trials | Myeloma Trials

Acute Lymphoblastic Leukaemia (ALL) ALL06 II Enrolling
A Phase II trial of an intensive pediatric protocol incorporating post – induction stratification based on Minimal Residual Disease levels for the treatment of adolescents aged 15 years and above, and young adults aged up to 40 years, with newly diagnosed Acute Lymphoblastic Leukaemia (ALL)
Read more ...
Acute Myeloid Leukaemia (AML) AMLM16 II Enrolling
Sorafenib in combination with intensive chemotherapy for previously untreated adult FLT3-ITD positive AML: a Phase 2 randomised double-blind placebo controlled multi-centre study
Read more ...
Acute Myeloid Leukaemia (AML) AMLM17 I & II Enrolling
A Strategy of High-Dose Lenalidomide in Combination with Epigenetic Therapies for Relapsed or Refractory Acute Myeloid Leukaemia
Read more ...
Acute Myeloid Leukaemia (AML) AMLM20 II/III Enrolling
A programme of development for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome
Read more ...
Acute Myeloid Leukaemia (AML) AMLM21 II Enrolling
A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in FLT3-ITD positive acute myeloid leukaemia (PonAZA)
Read more ...
Acute Myeloid Leukaemia (AML) NBCR   Enrolling
Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry
Read more ...
Chronic Lymphocytic Leukemia (CLL) CLL6 III Enrolling
An Australasian, Phase III, Multicentre, Randomised trial comparing lenalidomide consolidation vs no consolidation in patients with Chronic Lymphocytic Leukemia and residual disease following induction chemotherapy (RESIDUUM)
Read more ...
Chronic Lymphocytic Leukemia (CLL) CLL07 II Enrolling
An Australasian, phase II, multicentre, randomised, study investigating safety and efficacy for dose reduced fludarabine, cyclophosphamide and i.v. obinutuzumab (G-FC3) versus oral chlorambucil and i.v. obinutuzumab (G-Clb) in previously untreated, comorbid (CIRS score >=6), elderly (>=65 years old) patients with chronic lymphocytic leukaemia (CLL)
Read more ...
Chronic Myeloid Leukaemia (CML) CML11 II Enrolling
Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase CML aiming to maximize Complete Molecular Response (CMR) and Major Molecular Response (MMR)
Read more ...
Chronic Myeloid Leukaemia (CML) CML12 II Enrolling
A single arm phase II study to individualize dasatinib dosing based on trough levels and molecular response to maintain efficacy whilst minimising toxicity
Read more ...
Low Grade Non-Hodgkin Lymphoma NHL26 II Enrolling
A Phase 2 Study of patients treated for relapsed Follicular Lymphoma: with Revlimid® consolidation added to Rituximab maintenance therapy in those remaining PET positive
Read more ...
High Grade Non-Hodgkin Lymphoma NHL29 II Enrolling
A Phase II Study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL
Read more ...
Myeloma MM16 II Enrolling
Phase II study assessing the effect of carfilzomib treatment on early free light chain kinetics in myeloma patients with renal impairment
Read more ...
Myeloma MM17 Enrolling
A multicentre single arm study of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (MM) patients refractory to initial bortezomib-based induction therapy
Read more ...
Myeloproliferative Neoplasms MPN01   Enrolling
Myeloproliferative neoplasms registry
Read more ...